Cilansetron NDA Submitted

Published Online: Friday, October 1, 2004

Cilansetron (also known as Calmactin; Solvay Pharmaceuticals, Marietta, Ga), a selective serotonin (5-hydroxytryptamine; 5-HT) type 3 (5-HT3) receptor antagonist, has shown promising efficacy in patients with irritable bowel syndrome with diarrhea (IBS-D). Results, however, from summary phase 3 data presented as an abstract and an oral presentation at the 105th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week (held from May 15 to 20, 2004, in New Orleans, La), raise questions regarding its safety, particularly in women. In a 6-month, double-blind, placebo-controlled study of 792 patients (358 men and 434 women) presented by Marc Bradette, MD, and colleagues, 12% of patients in the cilansetron group (n = 395) experienced constipation, compared with 3% in the placebo group (n = 397). In addition, 3 cases (of 395) of suspected ischemic colitis were reported in the cilansetron group.

A comprehensive appropriate-use program accompanied the recent cilansetron NDA submission to the FDA.

Latest Articles
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
Latest Issues